Outcomes of subsequent IVF cycles among women with PCOS after the first unstimulated IVM treatment: a single-center matched retrospective case-control study.
Ya-Lan Xu, Wei Guo, Yong-Xiu Hao, Shuo Yang, Rong Li, Xiao-Ying Zheng, Jie Qiao
{"title":"Outcomes of subsequent IVF cycles among women with PCOS after the first unstimulated IVM treatment: a single-center matched retrospective case-control study.","authors":"Ya-Lan Xu, Wei Guo, Yong-Xiu Hao, Shuo Yang, Rong Li, Xiao-Ying Zheng, Jie Qiao","doi":"10.1080/14767058.2024.2425756","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong><i>In-vitro</i> maturation (IVM) is an advanced technique and an alternative to conventional <i>in-vitro</i> fertilization (IVF). It is safe, effective, and cost-effective in patients with polycystic ovary syndrome (PCOS). However, no clinical guidelines state that IVM could work without compromised pregnancy outcomes in patients with PCOS. The purpose of this study was to identify whether previous unstimulated IVM improved the clinical outcomes of women with PCOS in the subsequent IVF cycle.</p><p><strong>Methods: </strong>In this matched retrospective case-control study, we compared the results of IVF treatment in two groups of women with PCOS between January 2008 and December 2017. The study group comprised 79 women who underwent a subsequent IVF treatment after IVM failure (IVM-IVF group). Considering the year, age, and BMI, a 1:3 matched control group of 237 women with PCOS who received their first IVF cycle was established (IVF group).</p><p><strong>Results: </strong>Compared with the IVF group, the IVM-IVF group had a significantly lower initial gonadotropin dose [112.5 IU (112.5-150 IU) <i>vs</i>. 150 IU (150-200 IU), <i>p</i> < 0.001] and total gonadotropin dose [1350 IU (1125-2162.5 IU) <i>vs</i>. 1875 IU (1425.00-2643.75 IU), <i>p</i> < 0.001]. The live birth rate, clinical pregnancy, and miscarriage rates were comparable between the IVM-IVF and IVF groups at 12 months [55.6% <i>vs</i>. 48.6%, (adjusted <i>p</i> = 0.923), 68.1% <i>vs</i>. 59% (adjusted <i>p</i> = 0.677), and 18.8% <i>vs</i>. 17.7% (adjusted <i>p</i> = 0.645), respectively] and the first transfer cycle [36.1% <i>vs</i>. 34.2% (adjusted <i>p</i> = 0.560), 55.6% <i>vs</i>. 41.9% (adjusted <i>p</i> = 0.177), and 35% <i>vs</i>. 18.3% (adjusted <i>p</i> = 0.396), respectively]. The occurrence of moderate/severe OHSS did not significantly differ between the groups [5.1% <i>vs</i>. 7.6% (adjusted <i>p</i> = 0.698)]. Notably, LH levels, the LH/FSH ratio, and androstenedione levels were significantly reduced in the IVM-IVF group after the IVM treatment.</p><p><strong>Conclusion: </strong>Alternatives to IVF are underappreciated in clinical practice and research because of the lack of evidence on the efficacy of IVM in certain populations. IVF treatment given during a follow-up visit after an unstimulated IVM can achieve pregnancy outcomes comparable to those of a first IVF cycle without adversely affecting the subsequent pregnancy outcome.</p>","PeriodicalId":50146,"journal":{"name":"Journal of Maternal-Fetal & Neonatal Medicine","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Maternal-Fetal & Neonatal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14767058.2024.2425756","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: In-vitro maturation (IVM) is an advanced technique and an alternative to conventional in-vitro fertilization (IVF). It is safe, effective, and cost-effective in patients with polycystic ovary syndrome (PCOS). However, no clinical guidelines state that IVM could work without compromised pregnancy outcomes in patients with PCOS. The purpose of this study was to identify whether previous unstimulated IVM improved the clinical outcomes of women with PCOS in the subsequent IVF cycle.
Methods: In this matched retrospective case-control study, we compared the results of IVF treatment in two groups of women with PCOS between January 2008 and December 2017. The study group comprised 79 women who underwent a subsequent IVF treatment after IVM failure (IVM-IVF group). Considering the year, age, and BMI, a 1:3 matched control group of 237 women with PCOS who received their first IVF cycle was established (IVF group).
Results: Compared with the IVF group, the IVM-IVF group had a significantly lower initial gonadotropin dose [112.5 IU (112.5-150 IU) vs. 150 IU (150-200 IU), p < 0.001] and total gonadotropin dose [1350 IU (1125-2162.5 IU) vs. 1875 IU (1425.00-2643.75 IU), p < 0.001]. The live birth rate, clinical pregnancy, and miscarriage rates were comparable between the IVM-IVF and IVF groups at 12 months [55.6% vs. 48.6%, (adjusted p = 0.923), 68.1% vs. 59% (adjusted p = 0.677), and 18.8% vs. 17.7% (adjusted p = 0.645), respectively] and the first transfer cycle [36.1% vs. 34.2% (adjusted p = 0.560), 55.6% vs. 41.9% (adjusted p = 0.177), and 35% vs. 18.3% (adjusted p = 0.396), respectively]. The occurrence of moderate/severe OHSS did not significantly differ between the groups [5.1% vs. 7.6% (adjusted p = 0.698)]. Notably, LH levels, the LH/FSH ratio, and androstenedione levels were significantly reduced in the IVM-IVF group after the IVM treatment.
Conclusion: Alternatives to IVF are underappreciated in clinical practice and research because of the lack of evidence on the efficacy of IVM in certain populations. IVF treatment given during a follow-up visit after an unstimulated IVM can achieve pregnancy outcomes comparable to those of a first IVF cycle without adversely affecting the subsequent pregnancy outcome.
目的:体外成熟(IVM)是一种先进的技术,也是传统体外受精(IVF)的替代方法。对于多囊卵巢综合症(PCOS)患者来说,它安全、有效且经济实惠。然而,目前还没有临床指南规定体外受精术可以在不影响多囊卵巢综合症患者妊娠结果的情况下发挥作用。本研究的目的是确定先前的非刺激性体外受精是否能改善多囊卵巢综合征妇女在随后的体外受精周期中的临床结果:在这项匹配的回顾性病例对照研究中,我们比较了两组多囊卵巢综合征女性患者在 2008 年 1 月至 2017 年 12 月期间的 IVF 治疗结果。研究组包括79名在IVM失败后接受后续IVF治疗的女性(IVM-IVF组)。考虑到年份、年龄和体重指数,建立了一个1:3的配对对照组(IVF组),其中包括237名首次接受IVF周期治疗的多囊卵巢综合征女性患者:结果:与 IVF 组相比,IVM-IVF 组的初始促性腺激素剂量明显较低[112.5 IU (112.5-150 IU) vs. 150 IU (150-200 IU),p vs. 1875 IU (1425.00-2643.75 IU),p vs. 48.6%(调整后 p = 0.923),68.1% vs. 59%(调整后 p = 0.923)]。59%(调整后 p = 0.677)和 18.8% vs. 17.7%(调整后 p = 0.645)]以及第一个移植周期[分别为 36.1% vs. 34.2%(调整后 p = 0.560)、55.6% vs. 41.9%(调整后 p = 0.177)和 35% vs. 18.3%(调整后 p = 0.396)]。中度/重度OHSS的发生率在两组间无明显差异[5.1% vs. 7.6%(调整后p = 0.698)]。值得注意的是,IVM-IVF组的LH水平、LH/FSH比值和雄烯二酮水平在IVM治疗后显著降低:结论:由于缺乏IVM在某些人群中的疗效证据,IVF的替代方案在临床实践和研究中未得到充分重视。在非刺激性体外受精后的随访期间进行体外受精治疗,可获得与第一个体外受精周期相当的妊娠结果,而不会对随后的妊娠结果产生不利影响。
期刊介绍:
The official journal of The European Association of Perinatal Medicine, The Federation of Asia and Oceania Perinatal Societies and The International Society of Perinatal Obstetricians. The journal publishes a wide range of peer-reviewed research on the obstetric, medical, genetic, mental health and surgical complications of pregnancy and their effects on the mother, fetus and neonate. Research on audit, evaluation and clinical care in maternal-fetal and perinatal medicine is also featured.